TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: In our cohort, survival outcomes did not differ by CD30 status, reinforcing the view that CD30 expression—while biologically relevant to the mechanism of BV—may be an imperfect surrogate for clinical benefit in AITL or PTCL-NOS.